AusCann Group (ASX:AC8) cannabis product performs well in dog study

CPAT-01 is a standardised pharmaceutical product, derived from natural THC and CBD extracts and formulated into a liquid oral solution. The phase 2A pilot study was a world-first, randomised, double-blind, placebo-controlled clinical trial. AusCann has now received a full analysis of the trial’s clinical pain and lameness results, which indicate that CPAT-01 improved the pain, […]